Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2024 | MRD as a surrogate endpoint for AML therapy

Christopher Hourigan • 4 Sep 2024
SOHO 2024
Acute Myeloid Leukemia Leukemia

Christopher Hourigan, MD, DPhil, Virginia Tech FBRI Cancer Research Center, Washington, DC, outlines the uses of measurable residual disease (MRD) in acute myeloid leukemia (AML) and highlights its potential as a surrogate endpoint for accelerating regulatory approval in the drug development space. Dr Hourigan discusses some consortiums formed with this goal in mind. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Christopher Hourigan

Improving transplant outcomes in AML
Improving transplant outcomes in AML
Charles Craddock et al. • 12 Apr 2023
The importance of measurable residual FLT3-ITD before alloSCT for AML
1:33
The importance of measurable residual FLT3-ITD before alloSCT for AML
Christopher Hourigan • 4 Sep 2024
Determining complete remission in patients with AML
1:18
Determining complete remission in patients with AML
Christopher Hourigan • 4 Sep 2024
Updates in the diagnosis, classification & risk stratification of MDS
Updates in the diagnosis, classification & risk stratification of MDS
Christopher Hourigan et al. • 17 Jul 2024

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals